clinical-collaboration-with-Amgen
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS ™ (sotorasib), a KRASG12C InhibitorCombination of leading SOS1::pan-KRAS inhibitor with the first US FDA approved KRASG12C inhibitor has the potential to demonstrate additional therapeutic benefit for people living with KRAS G12C mutated cancers  The new clinical partnership adds to Boehringer Ingelheim ’s comprehensive program investigating combinations of its SOS1::pan-KRAS inhibitor, BI 1701963 with potentially synergistic approaches (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 16, 2021 Category: Research Source Type: news

New Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration-- Research collaboration covers multiple antibody research programs – (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX ® and Ingelvac PRRSFLEX EU® in the EUBoehringer Ingelheim launches first PCV-2 / PRRS vaccine combinationThis combination provides simple protection against two major respiratory pathogens in one shotIt also enhances the flexibility of vaccination protocols in pig production thus contributing to better pig well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

FRONTLINE ® becomes Brand of the Year 2021-22
FRONTLINE ® becomes Brand of the Year 2021-2022 in World Branding AwardsFRONTLINE ® was named global Brand of the Year (Animalis Edition) for 2021-2022The Award scores are predominantly constituted by consumer votesWorld Branding Awards recognize and celebrate some of the best global, regional and national brands for their work and achievement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)Breakthrough Designation awarded following empagliflozin ’s results in first and only successful trial for HFpEF (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 9, 2021 Category: Research Source Type: news

emperor-preserved-heart-failure-full-data
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction  In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21  percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1The benefit in the primary endpoint was independent of ejection fraction or diabetes status1Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for h...
Source: Boehringer Ingelheim Corporate News - August 27, 2021 Category: Research Source Type: news

Boehringer-Ingelheim's-half-year-figures-2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and developmentBreakthrough results in the treatment of a type of heart failure, which is extremely difficult to manageStrong progress in mental health pipelineGood business performance in all areas, despite ongoing impact of COVID-19 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 29, 2021 Category: Research Source Type: news

BI Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase  Analysis of first part of the TRISTARDS study (Phase 2b) investigating alteplase in patients with COVID-19 acute respiratory distress syndrome (ARDS) supports further developmentPhase 3 part of TRISTARDS to be initiated in Q4 2021SARS-CoV-2 neutralizing antibody development discontinued in light of evolving landscape including vaccination success and emerging variants (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 23, 2021 Category: Research Source Type: news

Odile Bain Memorial Prize 2021
: Brilliant early-career scientists in parasitology recognizedResearchers in the field of parasitology celebrated for contributions early in their scientific careersTogether with scientific publisher Parasites& Vector, Boehringer Ingelheim has sponsored the award since its founding in 2014Award serves to foster career growth in parasitology as well as keep memory of parasitologist Odile Bain alive (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2021 Category: Research Source Type: news

Flood-disaster-in-Germany-donation-from-Boehringer-Ingelheim
Flood disaster in Germany: Boehringer Ingelheim increases donation amount to EUR 1 millionDramatic situation requires rapid and comprehensive helpDonation of EUR 100,000 to the German Red CrossInitial measure with 2,300 meals for Ahrweiler district (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 16, 2021 Category: Research Source Type: news

FreVAX smartphone application piglet vaccination
New FreVAX ™ smartphone application brings piglet vaccination to another levelFreVAX ™ is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. This recent development has resulted from a partnership with Henke-Sass Wolf1Boehringer Ingelheim has introduced the FreVAX ™ app 2.0 that aims to enhance the interaction with the FreVAX™ device  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 9, 2021 Category: Research Source Type: news

emperor-preserved-heart-failure-toplineresults
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction  The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2W...
Source: Boehringer Ingelheim Corporate News - July 6, 2021 Category: Research Source Type: news

2021 ABCD Young Scientist Award feline health
2021 Young Scientist Award winners announcedYoung veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their outstanding work into feline SARS-CoV-2 infections and feline leukaemia virus, respectivelyBoehringer Ingelheim has been sponsoring the award since 2008 to help foster talent development in the feline health research communityAward represents important collaboration between Boehringer Ingelheim and the Advisory Board on Cat Diseases (ABCD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

PRRS vaccine celebrates 25 years in Europe
Boehringer Ingelheim celebrates 25 years to combat PRRS in EuropeBoehringer Ingelheim ’s PRRS vaccine celebrates 25 years of presence in EuropeThe Company has been offering a holistic approach to veterinarians and producers to control PRRS through collaborative research, innovative diagnostics and services (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes  Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211  EMPRISE data complemen...
Source: Boehringer Ingelheim Corporate News - June 28, 2021 Category: Research Source Type: news

reduced-heart-failure-treatment-approval-europe
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fractionThis new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR of ≥20ml/min/1.73 m2Heart failure is the leading cause of hospitalization in Europe,   with prevalence expected to increase as the population agesJardiance was first approved in May 2014 for the treatment of adults ...
Source: Boehringer Ingelheim Corporate News - June 21, 2021 Category: Research Source Type: news

founding-member-of-QUTAC
Quantum Computing: Boehringer Ingelheim is a Founding Member of QUTACTen leading German companies form this newly created Quantum Technology and Application ConsortiumTogether, the members want to explore industrial applications for quantum computingQuantum computing has also great potential for pharmaceutical research and development (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 9, 2021 Category: Research Source Type: news

Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaksLifebit ’s deep learning, Natural Language Processing and Artificial Intelligence platform automatically detects and tracks global infectious disease outbreaks using real-world evidenceThe captured insights can accelerate detection of the latest outbreaks including transboundary diseases and emerging pathogens (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news

Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH  FDA ’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH.Boehringer Ingelheim ’s focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 2, 2021 Category: Research Source Type: news

BTD for GlyT1 in Schizophrenia
Boehringer Ingelheim ’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy DesignationBI 425809, a novel glycine transporter-1 (Gly-T1) inhibitor to be Studied in First-of-its-Kind Phase III Trials, Incorporating Speech Analytics and Virtual Reality Functional Capacity Assessments. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 24, 2021 Category: Research Source Type: news

emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure  The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 21, 2021 Category: Research Source Type: news

collaboration-Yale
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 10, 2021 Category: Research Source Type: news

Blue internal teat sealant now in dairy mastitis portfolio
Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolioBoehringer Ingelheim continues to stay at the forefront of innovation and provide producers with the right tools for disease preventionThe Company ’s Ubroseal® Blue brings confidence of best practice when it comes to sealant administration and removal (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news

expanded-collaboration-MD-Anderson
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer  Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC)  The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news

Clinical-phase2-trials-NASH-and-obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and ObesityNew studies mark an important advancement of Boehringer Ingelheim ’s cardiometabolic focus areas obesity and NASH.The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvementThe Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020.   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 13, 2021 Category: Research Source Type: news

PREVEXXION ® RN: Marek’s disease vaccine available in EU UK
PREVEXXION ® RN: the next generation of Marek’s disease vaccines now available in the EU and the UKPREVEXXION ® RN is the results of unprecedented engineering design in vaccinology which brings optimal safety and efficacy balanceThe product ’s early Marek’s disease onset of immunity from five days of age provides full protection of broilers, layers and breeders against the most virulent Marek’s disease virus strainsIt is also fully compatible with VAXXITEK ® HVT+IBD and available in the same ampoule for added convenience (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 8, 2021 Category: Research Source Type: news

2020-Positive-business-momentum-despite-COVID-19-impact
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19  Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus  Overall R&D investment up 7% to 3.7 billion EUR in 2020 (18.9% of net sales)  Outlook 2021: slight year-on-year increase in net sales on a comparable basis   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 23, 2021 Category: Research Source Type: news

collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric DisordersThrough the partnership with the Lieber Institute, Boehringer Ingelheim obtains access to preclinical pipeline candidates of a potential first-in-class approach for the symptomatic treatment of neuropsychiatric disorders, including schizophrenia.  The new collaboration further expands Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and solidifies the company’s commitment to provide better treatments for patients li...
Source: Boehringer Ingelheim Corporate News - March 16, 2021 Category: Research Source Type: news

Stop of treatment in COVID-19 study
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19Phase II study assessing BI 764198, a novel first-in-class compound, for patients hospitalized with COVID-19 with respiratory complications discontinued due to lack of efficacy in this indicationBoehringer Ingelheim remains committed to other research and development efforts in COVID-19 including new SARS-CoV-2 neutralizing antibodies (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 12, 2021 Category: Research Source Type: news

Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra Join Forces to Identify and  Validate Innovative Peptides for the Treatment of ObesityThe research agreement builds upon the successful relationship between Boehringer Ingelheim and Gubra and expands Boehringer Ingelheim ’s research into approaches with first in class potential for the treatment of obesity Obesity is a complex cardiometabolic disease with growing global prevalence and limited treatment options that are not sufficiently effective or are associated with adverse events (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 1, 2021 Category: Research Source Type: news

ATM-Ranking-2021
Access-To-Medicine: Ranking Progress and Focus on Early-Phase R&DBoehringer Ingelheim climbs two more places to rank 12 in 2021  Access-To-Medicine Index ​New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected in index criteriaWide range of projects addressing health challenges in low- and middle-income countries recognized (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 26, 2021 Category: Research Source Type: news

global-top-employer
Award: Boehringer Ingelheim is Global Top Employer 2021 Boehringer Ingelheim is one of sixteen top employers worldwide Awards in 27 countries and in Europe and the Latin America and Asia-Pacific regions Boehringer Ingelheim performs particularly well in strategy, corporate culture and employee involvement (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 21, 2021 Category: Research Source Type: news

Boehringer Ingelheim partners with PetMedix
Boehringer Ingelheim has entered into a partnership with PetMedix, a UK based research and development stage biopharmaceutical company.Strengthening partnerships to accelerate innovation and growth is now one of the key elements of Boehringer Ingelheim ’s refocused strategy. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim receives EMA marketing authorization  for NexGard® COMBO, the first isoxazoline-based full endectocide for catsThe product features a triple action formula that includes esafoxolaner – the newly developed form of afoxolaner - combined with eprinomectin and praziquantel.This innovative broad spectrum topical parasiticide is easy and convenient for cat owners.It kills a wider range of parasites than any other product on the market, covering core external parasites like fleas and ticks as well as internal parasites, including tapeworms. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies  Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancersLatest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim ’s position in the cancer vaccine and T-cell engager spacesAgreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio ’s  EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic a...
Source: Boehringer Ingelheim Corporate News - January 12, 2021 Category: Research Source Type: news

Partnering-with-google-in-quantum-computing
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D  Quantum computing offers the potential to significantly accelerate and optimize the discovery of future new medicines for patientsScientists from both companies will be breaking new ground in the application of quantum computing to molecular dynamics simulationsBoehringer Ingelheim has set up a dedicated Quantum Lab with leading experts  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 9, 2021 Category: Research Source Type: news

Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol ® IleitisThe Paul Ehrlich Institute (PEI) accepted new language on the label of Enterisol ® Ileitis, the only global oral live Lawsonia intracellularis vaccine to control Ileitis in swine.Boehringer Ingelheim strives to continuously bring innovation to the market to improve animal health. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 21, 2020 Category: Research Source Type: news

SARS-CoV-2-Neutralizing-Antibody-enters-Clinical-Phase
New SARS-CoV-2 Neutralizing Antibody enters Clinical PhaseCologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and preventionBI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical researchPhase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2020 Category: Research Source Type: news

Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates  Acquisition will add another key dimension to Boehringer Ingelheim ’s focus on patients with difficult-to-treat solid tumors NBE-Therapeutics ’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform NBE-Therapeutics ’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 10, 2020 Category: Research Source Type: news

Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to Acquire Labor Dr. Merk& Kollegen to Strengthen its Next Generation Cancer Immunology ProgramBoehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk& KollegenTransaction expands Boehringer Ingelheim ’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatmentsBoehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 9, 2020 Category: Research Source Type: news

Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health.The International Poultry Council represents a unified and harmonized voice of the poultry industry. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer  New collaboration strengthens Boehringer Ingelheim ’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancersProxygen ’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 7, 2020 Category: Research Source Type: news

bix_facilitates_global_partnerships
Boehringer Ingelheim: Digital Lab BI X Facilitates Global PartnershipsPartnerships play an essential role for BI X in creating digitally innovative products and services to accelerate the development of better healthcare for humans and animalsAmong other topics, BI X is searching for partners in the areas of complex neurological rehabilitation and single-cell multimodal omics technologiesSecond hub in Shanghai and new partnership platform to provide more cooperation (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 30, 2020 Category: Research Source Type: news

empa-reg-outcome-recurrent-events
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and s...
Source: Boehringer Ingelheim Corporate News - November 18, 2020 Category: Research Source Type: news

Positive-CHMP-opinion-for-dabigatran-in-children
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa ® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of ageNo approved therapy for the treatment and prevention of venous thromboembolic events in children until nowCurrent standard of care often associated with frequent monitoring of anticoagulation or daily injections1Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran ´s established and well-documented safety and effic...
Source: Boehringer Ingelheim Corporate News - November 13, 2020 Category: Research Source Type: news

new_analysis_nintedanib_SSc_ILD
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1  Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS ® trial, according to this analysis1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2020 Category: Research Source Type: news

Developing-potential-treatment-for-severe-COVID
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news

Developing-potential-treatment-for-severe-COVID19-complications
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news

Boehringer Ingelheim Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigsThis novel device will bring benefits to swine producers ensuring improved safety and efficacy of vaccinationForming new partnerships is fully aligned with part of Boehringer Ingelheim ’s animal health strategy, aiming to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 23, 2020 Category: Research Source Type: news

Purevax range now available in 0.5 ml presentation
Purevax ® range now available in 0.5 ml presentationBoehringer Ingelheim announces reduced volume vaccines for catsMore convenient vaccination experience combined with same efficacyPurevax ® is the only fully adjuvant‑free feline vaccine range (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news